Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma

Annals of Oncology

Volumn 13, Issue 11, 2002, Pages 1806-1809

  Baudin, E ^a   Docao, C ^a   Gicquel, C ^b   Vassal, G ^a   Bachelot, A ^a   Penfornis, A ^c   Schlumberger, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Adrenocortical carcinoma; Chemotherapy; CPT 11; Irinotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANDROGEN; ANTIEMETIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEOXYCORTICOSTERONE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROCORTISONE; IRINOTECAN; MITOTANE; NAVELBINE;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG RESPONSE; FEMALE; HUMAN; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

EID: 0036860302     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf291     Document Type: Article

References (22)

1. Luton JP, Cerdas S, Billaud L et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322: 1995-1201.
2. Pommier RF, Brennan MF. An 11-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963-971.
3. Soreide JA, Braband K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 1992; 16: 663-668.
4. Barzon L, Fallo F, Sonino N et al. Adrenocortical carcinoma: experience in 45 patients. Oncology 1997; 54: 490-496.
5. Schulick RD, Brennan MF. Long term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999; 6: 719-726.
6. Favia G, Lumachi F, D'Amico DF. Adrenocortical carcinoma: is prognosis different in nonfuctioning tumors? Results of surgical treatment in 31 patients. World J Surg 2001; 25: 735-738.
7. Kendrick ML, Lloyd R, Erickson L et al. Adrenocortical carcinoma. Surgical progress or status quo? Arch Surg 2001; 136: 543-549.
8. Icard P, Goudet P, Charpenay C. Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg 2001; 25: 891-897.
9. Vassilopoulou-Sellin R, Schultz PN. Adrenal cortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001; 92: 1113-1121.
10. Gicquel C, Baudin E, Lebouc Y, Schlumberger M. Adrenocortical carcinoma. Ann Oncol 1997; 8: 423-427.
11. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72: 3145-3155.
12. Bukowski RM, Wolfe M, Levine HS et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group Study. J Clin Oncol 1993; 11: 161-165.
13. Bonacci R, Gigliotti A, Baudin E et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenal cortical carcinoma. Br J Cancer 1998; 78: 546-549.
14. Berruti A, Terzolo M, Pia A et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 1998; 83: 2194-2200.
15. Williamson SK, Lew D, Miller GJ et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma. Cancer 2000; 88: 1159-1165.
16. Van Slooten H, Moolenaar AJ, Van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with 1,1-dichlorodiphenildichloroethane (o,p'DDD): prognostic implications of serum level monitoring. Eur J Clin Oncol 1984; 20: 47-53.
17. Haak HR, Hermans J, Van de Velde CJH et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-951.
18. Terzolo M, Pia A, Berruti A et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000; 85: 2234-2238.
19. Baudin E, Pellegriti G, Bonnay M et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001; 92: 1385-1392.
20. Corcuff JB, Logié A, Baudin E et al. Antimitotic drugs effects on adrenocortical tumour cells. Protective role of the autocrine IGF system. 82nd Annual Meeting of the Endocrine Society, 21-24 June 2000, Toronto, ON, Canada. (Abstr 736a).
21. Rothenberg ML, Kuhn JG, Schaaf LJ et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 2001; 12: 1631-1641.
22. Rothenberg ML. Irinothecan (CPT-11): recent developments and future directions-colorectal cancer and beyond. Oncologist 2001; 6: 66-80.